Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Olaf Penack

Showing results (151-160 of 184) with videos related to

Pageof 19
Sort By:
Science Advances|September 22, 2023
Severe hematotoxicity after CD19 CAR-T therapy is associated with suppressive immune dysregulation and limited CAR-T expansionKai Rejeski, Ariel Perez, Gloria Iacoboni, et al.
Bone Marrow Transplantation|January 16, 2026
Results of brexucabtagene-autoleucel for patients with relapsed/refractory Mantle Cell Lymphoma in the routine setting in Germany and SwitzerlandLinda Simon, Vladan Vucinic, Kai Rejeski, et al.
Hemasphere|October 6, 2023
Clinical Implications and Dynamics of Clonal Hematopoiesis in Anti-CD19 CAR T-cell Treated PatientsVictoria Panagiota, Johanna Franziska Kerschbaum, Olaf Penack, et al.
Bone Marrow Transplantation|August 12, 2023
Current incidence, severity, and management of veno-occlusive disease/sinusoidal obstruction syndrome in adult allogeneic HSCT recipients: an EBMT Transplant Complications Working Party studyTapani Ruutu, Christophe Peczynski, Mohamed Houhou, et al.
The Journal of Clinical Investigation|May 17, 2013
Adoptively transferred TRAIL+ T cells suppress GVHD and augment antitumor activityArnab Ghosh, Yildirim Dogan, Maxim Moroz, et al.
European Journal of Cancer (Oxford, England : 1990)|January 18, 2023
AGIHO guideline on evidence-based management of COVID-19 in cancer patients: 2022 update on vaccination, pharmacological prophylaxis and therapy in light of the omicron variantsNicola Giesen, Elena Busch, Enrico Schalk, et al.
Frontiers in Immunology|May 1, 2020
Association of Serum Ferritin Levels Before Start of Conditioning With Mortality After alloSCT - A Prospective, Non-interventional Study of the EBMT Transplant Complications Working PartyOlaf Penack, Christophe Peczynski, Steffie van der Werf, et al.
Bone Marrow Transplantation|May 13, 2026
Central nervous system complications after allogeneic haematopoietic cell transplantation: best practice recommendations from the EBMT practice harmonisation and guidelines committee on epidemiology, outcome and neuroimagingMartin Schmidt-Hieber, Roser Velasco, Olaf Penack, et al.
Plos One|July 16, 2011
Ceacam1 separates graft-versus-host-disease from graft-versus-tumor activity after experimental allogeneic bone marrow transplantationSydney X Lu, Lucy W Kappel, Anne-Marie Charbonneau-Allard, et al.
Bone Marrow Transplantation|May 7, 2026
Symptom-guided approach to central nervous system complications in allogeneic hematopoietic cell transplant recipients: Best practice recommendations from the EBMT Practice Harmonisation and Guidelines committeeRoser Velasco, Martin Schmidt-Hieber, Olaf Penack, et al.
Pageof 19

Showing results (151-160 of 184) with videos related to

Sort By:
Pageof 19
Science Advances|September 22, 2023
Severe hematotoxicity after CD19 CAR-T therapy is associated with suppressive immune dysregulation and limited CAR-T expansionKai Rejeski, Ariel Perez, Gloria Iacoboni, et al.
Bone Marrow Transplantation|January 16, 2026
Results of brexucabtagene-autoleucel for patients with relapsed/refractory Mantle Cell Lymphoma in the routine setting in Germany and SwitzerlandLinda Simon, Vladan Vucinic, Kai Rejeski, et al.
Hemasphere|October 6, 2023
Clinical Implications and Dynamics of Clonal Hematopoiesis in Anti-CD19 CAR T-cell Treated PatientsVictoria Panagiota, Johanna Franziska Kerschbaum, Olaf Penack, et al.
Bone Marrow Transplantation|August 12, 2023
Current incidence, severity, and management of veno-occlusive disease/sinusoidal obstruction syndrome in adult allogeneic HSCT recipients: an EBMT Transplant Complications Working Party studyTapani Ruutu, Christophe Peczynski, Mohamed Houhou, et al.
The Journal of Clinical Investigation|May 17, 2013
Adoptively transferred TRAIL+ T cells suppress GVHD and augment antitumor activityArnab Ghosh, Yildirim Dogan, Maxim Moroz, et al.
European Journal of Cancer (Oxford, England : 1990)|January 18, 2023
AGIHO guideline on evidence-based management of COVID-19 in cancer patients: 2022 update on vaccination, pharmacological prophylaxis and therapy in light of the omicron variantsNicola Giesen, Elena Busch, Enrico Schalk, et al.
Frontiers in Immunology|May 1, 2020
Association of Serum Ferritin Levels Before Start of Conditioning With Mortality After alloSCT - A Prospective, Non-interventional Study of the EBMT Transplant Complications Working PartyOlaf Penack, Christophe Peczynski, Steffie van der Werf, et al.
Bone Marrow Transplantation|May 13, 2026
Central nervous system complications after allogeneic haematopoietic cell transplantation: best practice recommendations from the EBMT practice harmonisation and guidelines committee on epidemiology, outcome and neuroimagingMartin Schmidt-Hieber, Roser Velasco, Olaf Penack, et al.
Plos One|July 16, 2011
Ceacam1 separates graft-versus-host-disease from graft-versus-tumor activity after experimental allogeneic bone marrow transplantationSydney X Lu, Lucy W Kappel, Anne-Marie Charbonneau-Allard, et al.
Bone Marrow Transplantation|May 7, 2026
Symptom-guided approach to central nervous system complications in allogeneic hematopoietic cell transplant recipients: Best practice recommendations from the EBMT Practice Harmonisation and Guidelines committeeRoser Velasco, Martin Schmidt-Hieber, Olaf Penack, et al.
Pageof 19